Protein tyrosine phosphatase non-receptor II: A possible biomarker of poor prognosis and mediator of immune evasion in hepatocellular carcinoma

Figure 4 Risk model construction based on protein tyrosine phosphatase non-receptor 2-associated immunomodulators in hepatocellular carcinoma. A: Prognostic immunomodulators associated with protein tyrosine phosphatase non-receptor 2 (PTPN2) in hepatocellular carcinoma (HCC); B and C: Cox proportional hazard regression model for prediction of HCC risk constructed with PTPN2-associated immune checkpoints TNFRSF4 and TNFSF4; D: According to the risk model, the prognosis of the high-risk group was significantly worse than that of the low-risk group; E and F: Univariate and multivariate Cox regression analyses of model risk score and clinical factors; G: Accuracy of the Cox regression model for risk prediction assessed using receiver operation characteristic curves. AUC: Area under the curve. ^aP < 0.05; ^bP < 0.01.